{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:54:59Z","timestamp":1781222099185,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH EY020617"],"award-info":[{"award-number":["NIH EY020617"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY022589"],"award-info":[{"award-number":["P30EY022589"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"UCSD","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.exer.2014.11.002","type":"journal-article","created":{"date-parts":[[2014,11,5]],"date-time":"2014-11-05T13:30:30Z","timestamp":1415194230000},"page":"74-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide"],"prefix":"10.1016","volume":"129","author":[{"given":"Chengyun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyuan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihui","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Sailor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2014.11.002_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","article-title":"Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection","volume":"110","author":"Beer","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2014.11.002_bib3","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","article-title":"Age-related macular degeneration is the leading cause of blindness","volume":"291","author":"Bressler","year":"2004","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.exer.2014.11.002_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Investigative Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2014.11.002_bib5","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1167\/iovs.10-6387","article-title":"Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2014.11.002_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1076\/ceyr.18.3.161.5366","article-title":"Intravitreal pharmacokinetics in rabbits of the foscarnet lipid prodrug: 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA)","volume":"18","author":"Cheng","year":"1999","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2014.11.002_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/bjo.2007.133587","article-title":"Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle","volume":"92","author":"Cheng","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2014.11.002_bib8","first-page":"284","article-title":"Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema","volume":"31","author":"Chew","year":"2011","journal-title":"Retina-J Ret Vit. Dis."},{"key":"10.1016\/j.exer.2014.11.002_bib9","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1167\/iovs.12-11172","article-title":"Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system","volume":"54","author":"Chhablani","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2014.11.002_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/092739490500192","article-title":"A\u00a0review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation","volume":"12","author":"Gaudio","year":"2004","journal-title":"Ocular Immunol. Inflamm."},{"key":"10.1016\/j.exer.2014.11.002_bib10","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s00417-005-1182-1","article-title":"Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis","volume":"243","author":"Gan","year":"2005","journal-title":"Graefe's archive Clin. Exp. Ophthalmol.\u00a0= Albrecht von Graefes Archiv fur klinische und Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2014.11.002_bib11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3109\/02713683.2012.692846","article-title":"Ganciclovir ophthalmic Gel 0.15%: safety and efficacy of a new treatment for Herpes Simplex keratitis","volume":"37","author":"Kaufman","year":"2012","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2014.11.002_bib12","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2014.11.002_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1089\/jop.2012.0205","article-title":"Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin","volume":"29","author":"Hartmann","year":"2013","journal-title":"J.\u00a0Ocular Pharmacol. Ther. : Official J. Assoc. Ocular Pharmacol. Ther."},{"key":"10.1016\/j.exer.2014.11.002_bib14","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal Aflibercept (VEGF Trap-eye) in Wet Age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2014.11.002_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jconrel.2014.01.003","article-title":"Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon","volume":"178","author":"Hou","year":"2014","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.exer.2014.11.002_bib16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0039-128X(00)00235-X","article-title":"Correlation between different gene expression assays designed to measure trans-activation potencies of systemic glucocorticoids","volume":"66","author":"Jaffuel","year":"2001","journal-title":"Steroids"},{"key":"10.1016\/j.exer.2014.11.002_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ophtha.2004.10.042","article-title":"Intraocular pressure elevation after intravitreal triamcinolone acetonide injection","volume":"112","author":"Jonas","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2014.11.002_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archopht.125.3.309","article-title":"Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema","volume":"125","author":"Kuppermann","year":"2007","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2014.11.002_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Archives Ophthalmol."},{"key":"10.1016\/j.exer.2014.11.002_bib20","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/eye.2013.79","article-title":"Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion","volume":"27","author":"Mayer","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.exer.2014.11.002_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/bjo.68.3.145","article-title":"Routes of clearance of radioactive water from the rabbit vitreous","volume":"68","author":"Moseley","year":"1984","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2014.11.002_bib22","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.1167\/iovs.13-13078","article-title":"Laser-induced intrachoroidal dexamethasone drug delivery system to posterior eye segment","volume":"54","author":"Murata","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2014.11.002_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.exer.2013.09.001","article-title":"Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles","volume":"116","author":"Nieto","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2014.11.002_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/17425247.1.1.99","article-title":"Periocular routes for retinal drug delivery","volume":"1","author":"Raghava","year":"2004","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.exer.2014.11.002_bib25","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.exer.2014.11.002_bib26","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1248\/bpb.23.1352","article-title":"Pharmacokinetic prediction of the ocular absorption of an instilled drug with ophthalmic viscous vehicle","volume":"23","author":"Sasaki","year":"2000","journal-title":"Biological Pharm. Bull."},{"key":"10.1016\/j.exer.2014.11.002_bib27","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.ophtha.2010.03.033","article-title":"Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application","volume":"117","author":"Shen","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2014.11.002_bib28","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1167\/iovs.08-2969","article-title":"Poly-\u03b5-caprolactone intravitreous devices: an in\u00a0vivo study","volume":"50","author":"Silva-Cunha","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2014.11.002_bib29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1600-0420.2006.00698.x","article-title":"Intravitreal steroids in the management of macular oedema","volume":"84","author":"Sivaprasad","year":"2006","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.exer.2014.11.002_bib30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/1521-4095(200006)12:12<859::AID-ADMA859>3.0.CO;2-0","article-title":"Chemical and biological applications of porous silicon technology","volume":"12","author":"Stewart","year":"2000","journal-title":"Adv. Mater."},{"key":"10.1016\/j.exer.2014.11.002_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/archophthalmol.2007.8","article-title":"Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans","volume":"126","author":"Vemulakonda","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2014.11.002_bib32","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/S0161-6420(02)01176-4","article-title":"Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate","volume":"109","author":"Weijtens","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2014.11.002_bib33","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.eye.6701476","article-title":"Epidemiology of diabetic retinopathy and macular oedema: a systematic review","volume":"18","author":"Williams","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.exer.2014.11.002_bib34","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ajo.2008.12.033","article-title":"Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or irvine-gass syndrome","volume":"147","author":"Williams","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2014.11.002_bib35","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1039\/c1cc10993f","article-title":"Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics","volume":"47","author":"Wu","year":"2011","journal-title":"Chem. Commun."},{"key":"10.1016\/j.exer.2014.11.002_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/jop.2007.0002","article-title":"Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model","volume":"23","author":"Xu","year":"2007","journal-title":"J.\u00a0Ocular Pharmacol. Ther. : Official J. Assoc. Ocular Pharmacol. Ther."},{"key":"10.1016\/j.exer.2014.11.002_bib37","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ophtha.2009.02.002","article-title":"Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review","volume":"116","author":"Yilmaz","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2014.11.002_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/IJN.S6428","article-title":"Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits","volume":"4","author":"Zhang","year":"2009","journal-title":"Int. J. Nanomed."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448351400298X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448351400298X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T12:07:29Z","timestamp":1589285249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448351400298X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":38,"alternative-id":["S001448351400298X"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2014.11.002","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2014.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}